Related Experiment Video
Updated: May 29, 2025
05:33
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
9.4K
Harnessing the FBXW7 Somatic Mutant R465C for Targeted Protein Degradation.
Ananya A Basu1,2, Chenlu Zhang1, Milad Rouhimoghadam3
1Department of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.
Journal of the American Chemical Society
|February 6, 2025
Summary
Targeted protein degradation can utilize mutant E3 ligases found in diseased cells. This approach expands therapeutic options by hijacking cellular machinery to eliminate specific disease-causing proteins.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Targeted protein degradation (TPD) is a therapeutic strategy that uses the cell's natural machinery to eliminate specific proteins.
- Expanding the range of E3 ligases for proteasome-dependent TPD can broaden its applications.
- Mutant E3 ligases present in diseased cells offer a potential avenue for selective TPD.
Purpose of the Study:
- To investigate the potential of a specific mutant E3 ligase, FBXW7 R465C, for targeted protein degradation.
- To demonstrate the feasibility of using disease-specific mutant E3 ligases in TPD strategies.
Main Methods:
- Utilized heterobifunctional compounds designed to link target proteins to the FBXW7 R465C E3 ligase.
- Assessed the degradation of target proteins mediated by the mutant FBXW7 E3 ligase in cellular models.
Main Results:
- Successfully demonstrated that the somatic mutant FBXW7 R465C can be leveraged by heterobifunctional compounds for targeted protein degradation.
- Validated the principle of using mutant E3 ligases exclusively found in diseased cells for TPD.
Conclusions:
- The FBXW7 R465C mutant is a viable E3 ligase for proteasome-dependent targeted protein degradation.
- Exploiting mutant E3 ligases in diseased cells represents a promising strategy for developing novel TPD therapeutics.
